Pre-erythrocytic malaria vaccines: Discovery and Clinical Development
$967,251ZIAFY2025AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 39153490Paper 37571809Paper 37265668Paper 34857495Paper 34310889Paper 34194041Paper 31621832Paper 31308085Paper 31017084Paper 30621913Paper 29522056Paper 29434602Paper 29079696Paper 28500801Paper 28216244Paper 28115674Paper 28077589Paper 27434123Paper 26428458Paper 26169272Paper 25914686Paper 25541998Paper 25405724Paper 24988386Paper 24893777Paper 23907270Paper 23176657Paper 23125449Paper 22403305Paper 21317536Paper 21288352
Abstract
In FY2025 we looked to further assess PfSPZ Vaccine (a malaria vaccine developed by Sanaria, consisting of radiation-attenuated, purified, cryopreserved Plasmodium falciparum sporozoites (SPZ) and second generation PfSPZ Vaccine LARC2 (Late liver stage-Arresting and Replication-Competent) in expanded populations (young children, women of child-bearing potential (WOCBP), pregnant women) but due to budgetary limitations we had to place clinical studies on hold for another year, and focused our efforts on preclinical studies instead.
View original record on NIH RePORTER →